Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.

Brachman, David G

Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. [electronic resource] - International journal of radiation oncology, biology, physics Apr 2015 - 961-7 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural

1879-355X

10.1016/j.ijrobp.2014.12.050 doi


Antineoplastic Agents, Alkylating--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Brain Neoplasms--mortality
Chemoradiotherapy--adverse effects
Dacarbazine--administration & dosage
Disease-Free Survival
Dose Fractionation, Radiation
Female
Glioblastoma--mortality
Humans
Male
Maximum Tolerated Dose
Metalloporphyrins--administration & dosage
Multivariate Analysis
Supratentorial Neoplasms--mortality
Temozolomide